SKYRIZI REAL
PATIENT STORIES

JONATHAN: My name is Jonathan, and I have moderate to severe Crohn’s disease.                                        

SUPER: JONATHAN
A REAL CROHN’S PATIENT

JONATHAN: Before I was diagnosed, managing my symptoms, I didn’t know enough to manage them that well. So, I would try diet adjustments, some lifestyle changes.

JONATHAN: I’d have to you know, create my own accommodations, knowing where the closest restroom is, or just having down days where I knew I couldn’t do much, and I just thought that that’s kinda who I am and it’s just something that I had to deal with.

JONATHAN: Traveling with Crohn’s disease can be tricky.

JONATHAN: A couple years ago, a business trip to Europe—go on a long flight, deal with the jetlag, and then also be focused for important meetings, knowing that, you know, I really wasn’t comfortable.

JONATHAN: This shouldn’t be the way I’m supposed to be living and really started making me want to seek answers.

SUPER: Started making me want TO SEEK ANSWERS

JONATHAN: The doctor and I had a meeting about treatment options.

JONATHAN: He brought up the term biologic, which was a new term for me. I don’t think I had really ever heard of it before or understood what that meant.

JONATHAN: I think I expressed some hesitation, which I felt was natural and he agreed with me.

JONATHAN: He felt that SKYRIZI would be right for me.

GRAPHIC: SKYRIZI Logo

LEGAL SUPER: SKYRIZI is a prescription medicine used to treat moderate to severe Crohn’s disease in adults.

JONATHAN: My doctor and I discussed the potential side effects of using SKYRIZI.

LEGAL SUPER: Please see Important Safety Information near the end of this video.

JONATHAN: So, I started experiencing relief after my second starter dose.

SUPER: Significant symptom RELIEF AT 4 WEEKS

LEGAL SUPER: In clinical trials, SKYRIZI helped achieve significant symptom relief as early as 4 weeks.

JONATHAN: You know, I noticed overall, I was feeling better. 

LEGAL SUPER: In clinical trials, SKYRIZI helped achieve significant symptom relief as early as 4 weeks.

JONATHAN: I’m just excited knowing that the restrictions I had placed upon myself, because of the symptoms, could be lifted.

JONATHAN: So after the symptoms were under control, you know, I was excited to just be able to just be out there. To be able to say yes.

SUPER: To be able to SAY YES

JONATHAN: To going out with the family, traveling, eating foods that I might have avoided.

JONATHAN: I was excited to be able to say yes. It was just a very empowering feeling.

GRAPHIC: SKYRIZI Logo

LEGAL SUPER: Please keep watching for Important Safety Information.

VO/SUPER:

USE AND IMPORTANT SAFETY INFORMATION

SKYRIZI® (risankizumab-rzaa) USE

SKYRIZI is a prescription medicine used to treat moderate to severe Crohn’s disease in adults.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SKYRIZI^® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

• Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:
  • fainting, dizziness, feeling lightheaded (low blood pressure)
  • swelling of your face, eyelids, lips, mouth, tongue, or throat
  • trouble breathing or throat tightness
  • chest tightness
  • skin rash, hives
  • itching

Infections:

SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

• Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
  • fever, sweats, or chills
  • cough
  • shortness of breath
  • blood in your mucus (phlegm)
  • muscle aches
  • warm, red, or painful skin or sores on your body different from your psoriasis
  • weight loss
  • diarrhea or stomach pain
  • burning when you urinate or urinating more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

• have any of the conditions or symptoms listed in the section “What is the most important information I should know about SKYRIZI?”
• have an infection that does not go away or that keeps coming back.
• have TB or have been in close contact with someone with TB.
• have recently received or are scheduled to receive an immunization (vaccine). Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.
• are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.
• become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 to enroll in this registry.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?”

Liver problems may happen while being treated for Crohn’s disease or ulcerative colitis: A person with Crohn’s disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment, and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.

The most common side effects of SKYRIZI in people treated for Crohn’s disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, urinary tract infection, and rash.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI (risankizumab-rzaa) is available in a 600 mg/10 mL vial for intravenous infusion and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

Please see the Full Prescribing Information, including the Medication Guide, for SKYRIZI.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.

© 2025 AbbVie. All rights reserved.

SKYRIZI® and its design are registered trademarks of AbbVie Biotechnology Ltd.

US-SKZG-250036